Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCC reversal of FXa DOAC anticoagulation in healthy older adults
NL-OMON53386Not yet recruiting
- Sponsor
- VarmX
- Start
- Apr 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of prothrombin complex concentrate, human, apixaban, edoxaban and rivaroxaban (8 arms), sponsored by VarmX. Primary endpoint: Pharmacodynamic parameters. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
prothrombin complex concentrate, humanapixabanedoxabanrivaroxaban
Beyond the preview
Go deeper on NL-OMON53386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53386.